1. Home
  2. Live Updates
  3. Evoke 02

Evoke 02 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Evoke 02. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Evoke 02 Today - Breaking & Trending Today

Sacituzumab Govitecan Plus Pembrolizumab Elicits Antitumor Activity in NSCLC

Sandip P. Patel, MD, discusses the exploration of sacituzumab govitecan in the EVOKE-01 and EVOKE-02 trials in NSCLC and expands on future treatment directions with the agent in this patient population. ....

San Diego , United States , Sandipp Patel , University Of California , Moores Cancer Center , International Association , Lung Cancer , Sacituzumab Govitecan , Evoke 01 , Evoke 02 ,

EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in Advanced NSCLC

Edward B. Garon, MD, MS, reviews data from the EVOKE-02 study, and the panel offers their thoughts on antibody-drug conjugates for the treatment of advanced NSCLC. ....

Edwardb Garon , Evolving Treatment Paradigm , Advanced Non , Small Cell Lung Cancer , Sacituzumab Govitecan Plus Pembrolizumab , Non Small Cell Lung Cancer , Advanced Non Small Cell Lung Cancer , Advanced Nsclc , Nsclc Treatment , Evoke 02 , Antibody Drug Conjugates , Sacituzumab Govitecan ,

Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study

Sandip P. Patel, MD, reviews data from the preliminary results of the EVOKE-02 study investigating sacituzumab govitecan plus pembrolizumab in first-line metastatic non–small cell lung cancer. ....

United States , Cobo Dols , Sacituzumab Govitecan , Reyes Cabanillas , Sandipp Patel , Metastatic Non , Small Cell Lung Cancer , Preliminary Results , Partnership With , World Conference , Lung Cancer , Non Small Cell Lung Cancer , Metastatic Non Small Cell Lung Cancer , Metastatic Nsclc , Evoke 02 , Pd L1 Inhibitor , Safety Data , Evoke 02 Results , Evoke 02 Data ,

First-Line Sacituzumab Govitecan Plus Pembrolizumab Shows Promising Early Activity in NSCLC

In a preliminary analysis of the phase 2 EVOKE-02 trial, the investigational combination regimen showed an objective response rate of 56% in previously untreated patients with metastatic non–small cell lung cancer (NSCLC). ....

Byoung Chul Cho , Yonsei University College Of Medicine , International Association , Lung Cancer , Chul Cho , Medical Oncology , Yonsei Cancer Center , Yonsei University College , Bill Grossman , Evoke 02 , Sacituzumab Govitecan ,